BPCR vs. ATST, PCT, PHLL, 3IN, BUR, JGGI, RCP, EMG, ABDN, and HGT
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Alliance Trust (ATST), Polar Capital Technology Trust (PCT), Petershill Partners (PHLL), 3i Infrastructure (3IN), Burford Capital (BUR), JPMorgan Global Growth & Income (JGGI), RIT Capital Partners (RCP), Man Group (EMG), abrdn (ABDN), and HgCapital Trust (HGT). These companies are all part of the "asset management" industry.
BioPharma Credit vs.
BioPharma Credit (LON:BPCR) and Alliance Trust (LON:ATST) are both financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.
Alliance Trust received 26 more outperform votes than BioPharma Credit when rated by MarketBeat users. Likewise, 73.33% of users gave Alliance Trust an outperform vote while only 64.62% of users gave BioPharma Credit an outperform vote.
BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 821.6%. Alliance Trust pays an annual dividend of GBX 26 per share. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Trust pays out 1,226.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
BioPharma Credit has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Alliance Trust has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Alliance Trust has a net margin of 92.17% compared to BioPharma Credit's net margin of 80.20%. Alliance Trust's return on equity of 17.93% beat BioPharma Credit's return on equity.
BioPharma Credit has higher revenue and earnings than Alliance Trust. Alliance Trust is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 6.9% of Alliance Trust shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by insiders. Comparatively, 2.4% of Alliance Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, BioPharma Credit had 1 more articles in the media than Alliance Trust. MarketBeat recorded 1 mentions for BioPharma Credit and 0 mentions for Alliance Trust. BioPharma Credit's average media sentiment score of 0.66 beat Alliance Trust's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the media.
Summary
Alliance Trust beats BioPharma Credit on 9 of the 16 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy BPCR Stock Free BPCR Stock Alerts